Clinical Research Directory
Browse clinical research sites, groups, and studies.
Infusion of Apomorphine: Long-term Safety Study
Sponsor: MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Summary
This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or levodopa/carbidopa) and at least one other class of drugs or mode of therapy for PD.
Official title: A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available Therapy
Key Details
Gender
All
Age Range
30 Years - Any
Study Type
INTERVENTIONAL
Enrollment
99
Start Date
2015-02
Completion Date
2025-12
Last Updated
2025-06-19
Healthy Volunteers
No
Conditions
Interventions
apomorphine infusion
Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
Locations (18)
Phoenix, Arizona, United States
Loma Linda, California, United States
Los Angeles, California, United States
Los Angeles, California, United States
Aurora, Colorado, United States
Englewood, Colorado, United States
Boca Raton, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Kansas City, Kansas, United States
West Bloomfield, Michigan, United States
Albany, New York, United States
Cincinnati, Ohio, United States
Portland VA Medical Center
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Kirkland, Washington, United States